Authors: Shafran I, Kugler L, El-Zaatari FA, Naser SA, Sandoval J.
Institution: Department of Molecular Biology and Microbiology, University of Central Florida, Orlando, USA. ira@shafran.net
Background: Crohn's disease, an inflammatory bowel disease in humans, has a suspected aetiology of Mycobacterium avium subsp. Paratuberculosis.Results: Seven patients (19.4%) withdrew from the study since they were unable to tolerate medications. Of the remaining 29 patients, 21 (58.3%) reached a sustained state of improvement, traditionally defined as a decrease of 70 points between their entrance and exit Crohn's disease activity index scores together with the absence of the need of all other Crohn's medications, such as immunosuppressants and corticosteroids. Three Crohn's disease patients [8. 3%) noticed significant improvements, but required other Crohn's medications, concurrently with rifabutin and macrolide antibiotic therapy, to achieve and sustain improvement. Only 5 Crohn's disease patients (13.8%) were non-responders, noticing no marked improvement while on rifabutin and macrolide antibiotic therapy.
Conclusion: The data add further evidence to support the role of rifabutin and macrolide antibiotic therapy in the treatment of Crohn's disease specifically in those patients with evidence of Mycobacterium avium subsp. Paratuberculosis infection. A large multi-centre clinical trial is needed to further explore these findings.
Related Studies:
- Two-year-outcomes Analysis of Crohn's Disease Treated with Rifabutin and Macrolide Antibiotics
- Open Clinical Trial of Rifabutin and Clarithromycin Therapy in Crohn's Disease
